FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2568790842> ?p ?o ?g. }

• W2568790842 abstract "Abstract Abstract 2733 Poster Board II-709 Introduction: APO866, a reversible inhibitor of nicotinamide phosphoribosyltransferase (Nampt), acts by severely depleting intracellular NAD+ content and thus eliciting mitochondrial dysfunction, ATP depletion, and autophagic cell death. TNF-Related Apoptosis Inducing Ligand (TRAIL) binds to plasma membrane receptors DR4 and DR5 and causes apoptosis through activation of caspase-8 and caspase-10. These, in turn, activate effector caspases either directly or via Bid cleavage and subsequent initiation of the mitochondrial apoptotic pathway. In the present work, we have explored the interaction between APO866 and TRAIL in cellular models of hematological malignancies. Materials and Methods: The lymphoma cell lines Jurkat, PEER, MOLT-4, H9, and Namalwa, primary B-cell chronic lymphocytic leukemia (B-CLL) cells, as well as normal peripheral blood mononuclear cells (PBMCs) were treated with increasing concentrations of APO866, TRAIL, or with 1:1, 1:3, or 1:10 combinations of both agents for 72 hours (48 h APO866 + 24 h TRAIL). Cell death was assessed by propidium iodide staining and flow cytometry (FC). Apoptosis was assessed by Annexin V-propidium iodide staining and FC. Combination indices were calculated according to the Chou and Talalay method. DR5 membrane expression was assessed with a FITC-conjugated anti-DR5 antibody and FC after 12, 24, and 48 h exposure to APO866. Mitochondrial transmembrane potential (Δψm) and cell cycle analysis after single agent or combination treatment were determined by tetramethylrhodamine (TMRE) and Nicoletti staining, respectively, and FC. Intracellular NAD+ and ATP contents were quantified by cyclic assays and HPLC, respectively. The role of autophagy and of caspase activity in the cytotoxic activity of APO866, TRAIL, and of their combination was assessed using the PI3K inhibitors 3-methyladenine, LY2940002, and wortmannin, and the caspase inhibitors Z-VAD-FMK (pan-caspase inhibitor), Z-LEHD-FMK (caspase-9 inhibitor), and Z-IETD-FMK (caspase-8 inhibitor), respectively. Results/Discussion: APO866 induced NAD+ depletion, Δψm dissipation, and ATP exhaustion in the absence of caspase activation as detected by caspase-3 cleavage. Accordingly, autophagy but not caspase inhibitors blocked APO866 activity. Vice versa, TRAIL-induced apoptosis was blocked by the caspase inhibitors and enhanced by the PI3K inhibitors. Remarkably, APO866 and TRAIL showed a potent synergistic interaction in lymphoma cell lines and in primary B-CLL cells, consistently exhibiting combination indices below 1 upon exposure to a wide range of drugs concentrations. On the other hand, the two drugs and their combinations were poorly active and failed to show any cooperation in healthy PBMCs, indicating a specific activity against malignant cells. As a metabolic correlate of their interaction, TRAIL enhanced APO866-induced NAD+ depletion and Δψm. dissipation. As a result, lymphoma cells underwent massive ATP depletion and autophagic cell death. No DR5 upregulation at the cell surface of lymphoma cells was observed in response to APO866. Conclusions: APO866 and TRAIL show potent synergistic interaction in preclinical cell models of Non Hodgkin's Lymphoma and B-CLL. Due to the mild and manageable side effects of these two drugs in clinical trials, the addition of TRAIL to APO866 appears as an interesting option for the treatment of refractory hematological malignancies. Disclosures: No relevant conflicts of interest to declare." @default.
• W2568790842 created "2017-01-13" @default.
• W2568790842 creator A5000767355 @default.
• W2568790842 creator A5003509028 @default.
• W2568790842 creator A5006211032 @default.
• W2568790842 creator A5012691651 @default.
• W2568790842 creator A5015065739 @default.
• W2568790842 creator A5016794322 @default.
• W2568790842 creator A5018088896 @default.
• W2568790842 creator A5029781683 @default.
• W2568790842 creator A5036696968 @default.
• W2568790842 creator A5037494500 @default.
• W2568790842 creator A5042114293 @default.
• W2568790842 creator A5048339741 @default.
• W2568790842 creator A5056483394 @default.
• W2568790842 creator A5056680751 @default.
• W2568790842 creator A5057376855 @default.
• W2568790842 creator A5060112940 @default.
• W2568790842 creator A5071591293 @default.
• W2568790842 creator A5075260374 @default.
• W2568790842 creator A5078922292 @default.
• W2568790842 creator A5089884124 @default.
• W2568790842 date "2009-11-20" @default.
• W2568790842 modified "2023-09-28" @default.
• W2568790842 title "Potent Synergistic Activity of the NAD+ Synthesis Inhibitor APO866 and of the Apoptosis Inducer TRAIL in in Vitro and Ex Vivo Cellular Models of Non Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia." @default.
• W2568790842 doi "https://doi.org/10.1182/blood.v114.22.2733.2733" @default.
• W2568790842 hasPublicationYear "2009" @default.
• W2568790842 type Work @default.
• W2568790842 sameAs 2568790842 @default.
• W2568790842 citedByCount "0" @default.
• W2568790842 crossrefType "journal-article" @default.
• W2568790842 hasAuthorship W2568790842A5000767355 @default.
• W2568790842 hasAuthorship W2568790842A5003509028 @default.
• W2568790842 hasAuthorship W2568790842A5006211032 @default.
• W2568790842 hasAuthorship W2568790842A5012691651 @default.
• W2568790842 hasAuthorship W2568790842A5015065739 @default.
• W2568790842 hasAuthorship W2568790842A5016794322 @default.
• W2568790842 hasAuthorship W2568790842A5018088896 @default.
• W2568790842 hasAuthorship W2568790842A5029781683 @default.
• W2568790842 hasAuthorship W2568790842A5036696968 @default.
• W2568790842 hasAuthorship W2568790842A5037494500 @default.
• W2568790842 hasAuthorship W2568790842A5042114293 @default.
• W2568790842 hasAuthorship W2568790842A5048339741 @default.
• W2568790842 hasAuthorship W2568790842A5056483394 @default.
• W2568790842 hasAuthorship W2568790842A5056680751 @default.
• W2568790842 hasAuthorship W2568790842A5057376855 @default.
• W2568790842 hasAuthorship W2568790842A5060112940 @default.
• W2568790842 hasAuthorship W2568790842A5071591293 @default.
• W2568790842 hasAuthorship W2568790842A5075260374 @default.
• W2568790842 hasAuthorship W2568790842A5078922292 @default.
• W2568790842 hasAuthorship W2568790842A5089884124 @default.
• W2568790842 hasConcept C153911025 @default.
• W2568790842 hasConcept C179464577 @default.
• W2568790842 hasConcept C185592680 @default.
• W2568790842 hasConcept C190283241 @default.
• W2568790842 hasConcept C203014093 @default.
• W2568790842 hasConcept C2775934118 @default.
• W2568790842 hasConcept C2776090121 @default.
• W2568790842 hasConcept C2777938653 @default.
• W2568790842 hasConcept C2778461978 @default.
• W2568790842 hasConcept C31573885 @default.
• W2568790842 hasConcept C502942594 @default.
• W2568790842 hasConcept C55493867 @default.
• W2568790842 hasConcept C86803240 @default.
• W2568790842 hasConcept C88634738 @default.
• W2568790842 hasConcept C8891405 @default.
• W2568790842 hasConcept C95444343 @default.
• W2568790842 hasConcept C98424977 @default.
• W2568790842 hasConceptScore W2568790842C153911025 @default.
• W2568790842 hasConceptScore W2568790842C179464577 @default.
• W2568790842 hasConceptScore W2568790842C185592680 @default.
• W2568790842 hasConceptScore W2568790842C190283241 @default.
• W2568790842 hasConceptScore W2568790842C203014093 @default.
• W2568790842 hasConceptScore W2568790842C2775934118 @default.
• W2568790842 hasConceptScore W2568790842C2776090121 @default.
• W2568790842 hasConceptScore W2568790842C2777938653 @default.
• W2568790842 hasConceptScore W2568790842C2778461978 @default.
• W2568790842 hasConceptScore W2568790842C31573885 @default.
• W2568790842 hasConceptScore W2568790842C502942594 @default.
• W2568790842 hasConceptScore W2568790842C55493867 @default.
• W2568790842 hasConceptScore W2568790842C86803240 @default.
• W2568790842 hasConceptScore W2568790842C88634738 @default.
• W2568790842 hasConceptScore W2568790842C8891405 @default.
• W2568790842 hasConceptScore W2568790842C95444343 @default.
• W2568790842 hasConceptScore W2568790842C98424977 @default.
• W2568790842 hasLocation W25687908421 @default.
• W2568790842 hasOpenAccess W2568790842 @default.
• W2568790842 hasPrimaryLocation W25687908421 @default.
• W2568790842 hasRelatedWork W1980517164 @default.
• W2568790842 hasRelatedWork W2017168297 @default.
• W2568790842 hasRelatedWork W2029206266 @default.
• W2568790842 hasRelatedWork W2049503637 @default.
• W2568790842 hasRelatedWork W2104130860 @default.
• W2568790842 hasRelatedWork W2137300889 @default.
• W2568790842 hasRelatedWork W2146504802 @default.
• W2568790842 hasRelatedWork W2182785517 @default.
• W2568790842 hasRelatedWork W2332189755 @default.
• W2568790842 hasRelatedWork W2335526988 @default.
• W2568790842 hasRelatedWork W2383905372 @default.
• W2568790842 hasRelatedWork W2388440543 @default.

• next